Tag: Lung Cancer Liquid Biopsy Market Research Report

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Lung Cancer Liquid Biopsy Market Forecast Highlighting Growth From $1.3 Billion To $2.42 Billion

The market for liquid biopsies targeting lung cancer has experienced substantial expansion lately. Projections indicate a rise from $1.12 billion in 2025 to $1.31 billion by 2026, demonstrating a compound annual growth rate of 17.0%. This historical growth trajectory is supported by factors such as a rising prevalence of lung cancer, the inherent challenges associated with traditional tissue biopsy methods, progress made in molecular diagnostic techniques, the accessibility of technologies for detecting circulating biomarkers, and a surge in research endeavors within the field of oncology.

The market for liquid biopsies in lung cancer diagnosis is poised for substantial expansion in the coming years, projected to reach $2.42 billion by 2030 with a compound annual growth rate (CAGR) of 16.7%. This upward trajectory is fueled by several key factors, including a heightened demand for personalized cancer treatment strategies, the broadening scope of liquid biopsy applications in clinical settings, an increasing reliance on companion diagnostics, the growing integration of artificial intelligence for data analysis, and a stronger emphasis on early cancer detection initiatives. Furthermore, significant trends shaping this market during the forecast period involve a greater acceptance of non-invasive diagnostic methods, a rise in the utilization of next-generation sequencing (NGS) for liquid biopsy testing, a surging need for early cancer identification, the continuous development of personalized diagnostic tools for oncology, and improved integration of bioinformatics platforms.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24593&type=smp

Lung Cancer Liquid Biopsy Market Expansion Supported By Key Demand Factors

The anticipated rise in lung cancer cases is poised to be a significant catalyst for the expansion of the lung cancer liquid biopsy market. This malignancy, defined by the aberrant proliferation of cellular material within the pulmonary tissues and frequently linked to tobacco consumption and exposure to harmful environmental agents, is experiencing a surge primarily attributed to persistent tobacco usage. The carcinogenic elements inhaled through smoking initiate aberrant cellular development, thereby fueling the escalating rates of lung cancer. Liquid biopsies for lung cancer offer a crucial advantage by identifying specific genetic alterations associated with cancer and circulating tumor DNA from a simple blood draw, thereby facilitating prompt diagnosis, guiding therapeutic choices, and enabling the tracking of disease advancement or the efficacy of treatments. For illustration, recent data from the American Cancer Society, a research organization based in the United States, projected that in 2023, approximately 238,340 diagnoses of lung cancer would be made, with 117,550 among men and 120,790 among women, and an estimated 127,070 fatalities from the disease. Consequently, the growing prevalence of lung cancer is directly stimulating the market for liquid biopsy solutions.

Lung Cancer Liquid Biopsy Market Segment Outlook: Which Categories Are Expanding The Fastest?

The lung cancer liquid biopsy market covered in this report is segmented –

1) By Product: Instruments, Consumables, Kits And Reagents, Software And Services

2) By Technology: Multi-Gene-Parallel Analysis (Ngs), Single-Gene Analysis (PCR Microarrays)

3) By Biomarker: Cell-Free Deoxyribonucleic Acid, Circulating Tumor Deoxyribonucleic Acid, Extracellular Vesicles, Circulating Tumor Cells, Other Biomarkers

4) By Clinical Application: Therapy Selection, Treatment Monitoring, Early Cancer Screening, Recurrence Monitoring, Other Applications

5) By End User: Diagnostics And Imaging Centres, Hospitals, Academics And Research Centers, Other End Users

Subsegments:

1) By Instruments: PCR Instruments, Microarray Instruments, Next-Generation Sequencing (NGS) Instruments

2) By Consumables Kits And Reagents: Sample Collection Kits, Amplification Reagents, Sequencing Reagents

3) By Software And Services: Data Analysis Software, Cloud-Based Services, Bioinformatics Tools

Lung Cancer Liquid Biopsy Market Growth Trends Influencing Competitive Dynamics

Companies leading the lung cancer liquid biopsy sector are prioritizing innovation in technologies like blood-based screening for lung cancer to bolster early detection, refine diagnostic precision, and facilitate unobtrusive, continuous tracking of disease advancement and therapeutic effectiveness. This non-invasive method of screening for lung cancer involves examining biological markers within the blood to identify the disease in its nascent stages. As an illustration, DELFI Diagnostics Inc., a US biotechnology firm, introduced FirstLook Lung in October 2023, a liquid biopsy blood test engineered for the early identification of lung cancer. This test utilizes fragmentomics, achieving high sensitivity in detecting early lung cancer and boasting a 99.8% negative predictive value, positioning it as a practical and readily available initial assessment for individuals at risk, with the aim of enhancing early detection rates, promoting greater screening participation, and guiding imaging resources toward those most likely to gain from them.

Lung Cancer Liquid Biopsy Market Key Companies And Competitive Benchmarking

Major companies operating in the lung cancer liquid biopsy market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Biocept Inc., Agilent Technologies Inc., Eurofins Scientific, Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Natera Inc., Myriad Genetics Inc., NeoGenomics Laboratories Inc., Guardant Health Inc., Exosome Diagnostics Inc., Menarini Silicon Biosystems S.p.A., Inivata Ltd, Lucence Diagnostics Pte Ltd, LungLife AI Inc., Biodesix Inc., Oncocyte Corporation

Access The Complete Lung Cancer Liquid Biopsy Market Report:

https://www.thebusinessresearchcompany.com/report/lung-cancer-liquid-biopsy-global-market-report

Lung Cancer Liquid Biopsy Market Geographic Analysis: Where Is Demand Growing The Fastest?

North Americawas the largest region in the lung cancer liquid biopsy market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the lung cancer liquid biopsy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Lung Cancer Liquid Biopsy Market Forecast Highlighting Growth From $1.3 Billion To $2.42 Billion

The market for liquid biopsies targeting lung cancer has experienced substantial expansion lately. Projections indicate a rise from $1.12 billion in 2025 to $1.31 billion by 2026, demonstrating a compound annual growth rate of 17.0%. This historical growth trajectory is supported by factors such as a rising prevalence of lung cancer, the inherent challenges associated with traditional tissue biopsy methods, progress made in molecular diagnostic techniques, the accessibility of technologies for detecting circulating biomarkers, and a surge in research endeavors within the field of oncology.

The market for liquid biopsies in lung cancer diagnosis is poised for substantial expansion in the coming years, projected to reach $2.42 billion by 2030 with a compound annual growth rate (CAGR) of 16.7%. This upward trajectory is fueled by several key factors, including a heightened demand for personalized cancer treatment strategies, the broadening scope of liquid biopsy applications in clinical settings, an increasing reliance on companion diagnostics, the growing integration of artificial intelligence for data analysis, and a stronger emphasis on early cancer detection initiatives. Furthermore, significant trends shaping this market during the forecast period involve a greater acceptance of non-invasive diagnostic methods, a rise in the utilization of next-generation sequencing (NGS) for liquid biopsy testing, a surging need for early cancer identification, the continuous development of personalized diagnostic tools for oncology, and improved integration of bioinformatics platforms.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24593&type=smp

Lung Cancer Liquid Biopsy Market Expansion Supported By Key Demand Factors

The anticipated rise in lung cancer cases is poised to be a significant catalyst for the expansion of the lung cancer liquid biopsy market. This malignancy, defined by the aberrant proliferation of cellular material within the pulmonary tissues and frequently linked to tobacco consumption and exposure to harmful environmental agents, is experiencing a surge primarily attributed to persistent tobacco usage. The carcinogenic elements inhaled through smoking initiate aberrant cellular development, thereby fueling the escalating rates of lung cancer. Liquid biopsies for lung cancer offer a crucial advantage by identifying specific genetic alterations associated with cancer and circulating tumor DNA from a simple blood draw, thereby facilitating prompt diagnosis, guiding therapeutic choices, and enabling the tracking of disease advancement or the efficacy of treatments. For illustration, recent data from the American Cancer Society, a research organization based in the United States, projected that in 2023, approximately 238,340 diagnoses of lung cancer would be made, with 117,550 among men and 120,790 among women, and an estimated 127,070 fatalities from the disease. Consequently, the growing prevalence of lung cancer is directly stimulating the market for liquid biopsy solutions.

Lung Cancer Liquid Biopsy Market Segment Outlook: Which Categories Are Expanding The Fastest?

The lung cancer liquid biopsy market covered in this report is segmented –

1) By Product: Instruments, Consumables, Kits And Reagents, Software And Services

2) By Technology: Multi-Gene-Parallel Analysis (Ngs), Single-Gene Analysis (PCR Microarrays)

3) By Biomarker: Cell-Free Deoxyribonucleic Acid, Circulating Tumor Deoxyribonucleic Acid, Extracellular Vesicles, Circulating Tumor Cells, Other Biomarkers

4) By Clinical Application: Therapy Selection, Treatment Monitoring, Early Cancer Screening, Recurrence Monitoring, Other Applications

5) By End User: Diagnostics And Imaging Centres, Hospitals, Academics And Research Centers, Other End Users

Subsegments:

1) By Instruments: PCR Instruments, Microarray Instruments, Next-Generation Sequencing (NGS) Instruments

2) By Consumables Kits And Reagents: Sample Collection Kits, Amplification Reagents, Sequencing Reagents

3) By Software And Services: Data Analysis Software, Cloud-Based Services, Bioinformatics Tools

Lung Cancer Liquid Biopsy Market Growth Trends Influencing Competitive Dynamics

Companies leading the lung cancer liquid biopsy sector are prioritizing innovation in technologies like blood-based screening for lung cancer to bolster early detection, refine diagnostic precision, and facilitate unobtrusive, continuous tracking of disease advancement and therapeutic effectiveness. This non-invasive method of screening for lung cancer involves examining biological markers within the blood to identify the disease in its nascent stages. As an illustration, DELFI Diagnostics Inc., a US biotechnology firm, introduced FirstLook Lung in October 2023, a liquid biopsy blood test engineered for the early identification of lung cancer. This test utilizes fragmentomics, achieving high sensitivity in detecting early lung cancer and boasting a 99.8% negative predictive value, positioning it as a practical and readily available initial assessment for individuals at risk, with the aim of enhancing early detection rates, promoting greater screening participation, and guiding imaging resources toward those most likely to gain from them.

Lung Cancer Liquid Biopsy Market Key Companies And Competitive Benchmarking

Major companies operating in the lung cancer liquid biopsy market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Biocept Inc., Agilent Technologies Inc., Eurofins Scientific, Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Natera Inc., Myriad Genetics Inc., NeoGenomics Laboratories Inc., Guardant Health Inc., Exosome Diagnostics Inc., Menarini Silicon Biosystems S.p.A., Inivata Ltd, Lucence Diagnostics Pte Ltd, LungLife AI Inc., Biodesix Inc., Oncocyte Corporation

Access The Complete Lung Cancer Liquid Biopsy Market Report:

https://www.thebusinessresearchcompany.com/report/lung-cancer-liquid-biopsy-global-market-report

Lung Cancer Liquid Biopsy Market Geographic Analysis: Where Is Demand Growing The Fastest?

North Americawas the largest region in the lung cancer liquid biopsy market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the lung cancer liquid biopsy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Lung Cancer Liquid Biopsy Market Forecast Highlighting Growth From $1.3 Billion To $2.42 Billion

The market for liquid biopsies targeting lung cancer has experienced substantial expansion lately. Projections indicate a rise from $1.12 billion in 2025 to $1.31 billion by 2026, demonstrating a compound annual growth rate of 17.0%. This historical growth trajectory is supported by factors such as a rising prevalence of lung cancer, the inherent challenges associated with traditional tissue biopsy methods, progress made in molecular diagnostic techniques, the accessibility of technologies for detecting circulating biomarkers, and a surge in research endeavors within the field of oncology.

The market for liquid biopsies in lung cancer diagnosis is poised for substantial expansion in the coming years, projected to reach $2.42 billion by 2030 with a compound annual growth rate (CAGR) of 16.7%. This upward trajectory is fueled by several key factors, including a heightened demand for personalized cancer treatment strategies, the broadening scope of liquid biopsy applications in clinical settings, an increasing reliance on companion diagnostics, the growing integration of artificial intelligence for data analysis, and a stronger emphasis on early cancer detection initiatives. Furthermore, significant trends shaping this market during the forecast period involve a greater acceptance of non-invasive diagnostic methods, a rise in the utilization of next-generation sequencing (NGS) for liquid biopsy testing, a surging need for early cancer identification, the continuous development of personalized diagnostic tools for oncology, and improved integration of bioinformatics platforms.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24593&type=smp

Lung Cancer Liquid Biopsy Market Expansion Supported By Key Demand Factors

The anticipated rise in lung cancer cases is poised to be a significant catalyst for the expansion of the lung cancer liquid biopsy market. This malignancy, defined by the aberrant proliferation of cellular material within the pulmonary tissues and frequently linked to tobacco consumption and exposure to harmful environmental agents, is experiencing a surge primarily attributed to persistent tobacco usage. The carcinogenic elements inhaled through smoking initiate aberrant cellular development, thereby fueling the escalating rates of lung cancer. Liquid biopsies for lung cancer offer a crucial advantage by identifying specific genetic alterations associated with cancer and circulating tumor DNA from a simple blood draw, thereby facilitating prompt diagnosis, guiding therapeutic choices, and enabling the tracking of disease advancement or the efficacy of treatments. For illustration, recent data from the American Cancer Society, a research organization based in the United States, projected that in 2023, approximately 238,340 diagnoses of lung cancer would be made, with 117,550 among men and 120,790 among women, and an estimated 127,070 fatalities from the disease. Consequently, the growing prevalence of lung cancer is directly stimulating the market for liquid biopsy solutions.

Lung Cancer Liquid Biopsy Market Segment Outlook: Which Categories Are Expanding The Fastest?

The lung cancer liquid biopsy market covered in this report is segmented –

1) By Product: Instruments, Consumables, Kits And Reagents, Software And Services

2) By Technology: Multi-Gene-Parallel Analysis (Ngs), Single-Gene Analysis (PCR Microarrays)

3) By Biomarker: Cell-Free Deoxyribonucleic Acid, Circulating Tumor Deoxyribonucleic Acid, Extracellular Vesicles, Circulating Tumor Cells, Other Biomarkers

4) By Clinical Application: Therapy Selection, Treatment Monitoring, Early Cancer Screening, Recurrence Monitoring, Other Applications

5) By End User: Diagnostics And Imaging Centres, Hospitals, Academics And Research Centers, Other End Users

Subsegments:

1) By Instruments: PCR Instruments, Microarray Instruments, Next-Generation Sequencing (NGS) Instruments

2) By Consumables Kits And Reagents: Sample Collection Kits, Amplification Reagents, Sequencing Reagents

3) By Software And Services: Data Analysis Software, Cloud-Based Services, Bioinformatics Tools

Lung Cancer Liquid Biopsy Market Growth Trends Influencing Competitive Dynamics

Companies leading the lung cancer liquid biopsy sector are prioritizing innovation in technologies like blood-based screening for lung cancer to bolster early detection, refine diagnostic precision, and facilitate unobtrusive, continuous tracking of disease advancement and therapeutic effectiveness. This non-invasive method of screening for lung cancer involves examining biological markers within the blood to identify the disease in its nascent stages. As an illustration, DELFI Diagnostics Inc., a US biotechnology firm, introduced FirstLook Lung in October 2023, a liquid biopsy blood test engineered for the early identification of lung cancer. This test utilizes fragmentomics, achieving high sensitivity in detecting early lung cancer and boasting a 99.8% negative predictive value, positioning it as a practical and readily available initial assessment for individuals at risk, with the aim of enhancing early detection rates, promoting greater screening participation, and guiding imaging resources toward those most likely to gain from them.

Lung Cancer Liquid Biopsy Market Key Companies And Competitive Benchmarking

Major companies operating in the lung cancer liquid biopsy market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Biocept Inc., Agilent Technologies Inc., Eurofins Scientific, Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Natera Inc., Myriad Genetics Inc., NeoGenomics Laboratories Inc., Guardant Health Inc., Exosome Diagnostics Inc., Menarini Silicon Biosystems S.p.A., Inivata Ltd, Lucence Diagnostics Pte Ltd, LungLife AI Inc., Biodesix Inc., Oncocyte Corporation

Access The Complete Lung Cancer Liquid Biopsy Market Report:

https://www.thebusinessresearchcompany.com/report/lung-cancer-liquid-biopsy-global-market-report

Lung Cancer Liquid Biopsy Market Geographic Analysis: Where Is Demand Growing The Fastest?

North Americawas the largest region in the lung cancer liquid biopsy market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the lung cancer liquid biopsy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Larger Will The Lung Cancer Liquid Biopsy Market Become By 2030 Compared To 2026?

The lung cancer liquid biopsy market has witnessed rapid growth in recent years. Its value is projected to rise from $1.12 billion in 2025 to $1.31 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 17.0%. Several factors contributed to its historical expansion, including increasing lung cancer incidence rates, the limitations inherent in tissue biopsy procedures, advancements within molecular diagnostics, the widespread availability of circulating biomarker technologies, and the overall growth in oncology research activities.

The lung cancer liquid biopsy market size is projected for significant expansion in the coming years. This market is anticipated to reach $2.42 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 16.7%. Factors driving this growth during the forecast period include the increasing demand for precision oncology solutions, the broadening of liquid biopsy clinical applications, the rising adoption of companion diagnostics, the expanding integration of AI-driven data analysis, and an intensified focus on early cancer screening programs. Key trends identified for the forecast period encompass the increasing acceptance of non-invasive diagnostic techniques, the growing utilization of NGS-based liquid biopsy tests, an escalating demand for early cancer detection, the expansion of personalized oncology diagnostics, and improved integration of bioinformatics platforms.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24593&type=smp

What Influential Factors Are Boosting The Lung Cancer Liquid Biopsy Market Demand?

The rising occurrence of lung cancer is expected to propel the future growth of the lung cancer liquid biopsy market. Lung cancer is a medical condition defined by the uncontrolled multiplication of abnormal cells in the lungs, often triggered by smoking and environmental exposures. The primary reason for the increase in lung cancer cases is ongoing tobacco use, as smoking introduces carcinogens into the lungs that stimulate abnormal cell development. Lung cancer liquid biopsy aids by identifying cancer-related genetic mutations and tumor DNA from a blood sample, which enables early diagnosis, selection of suitable treatment, and monitoring of disease advancement or response to therapy. For instance, in January 2023, according to a report published by the American Cancer Society (ACS), a U.S.-based nonprofit organization, it was estimated that in 2023, 238,340 individuals, including 117,550 men and 120,790 women, would be diagnosed with lung cancer, and 127,070 people are expected to die from the disease. Therefore, the increasing incidence of lung cancer is driving the growth of the lung cancer liquid biopsy market.

What Are The Major Segment Categories Within The Lung Cancer Liquid Biopsy Market?

The lung cancer liquid biopsy market covered in this report is segmented –

1) By Product: Instruments, Consumables, Kits And Reagents, Software And Services

2) By Technology: Multi-Gene-Parallel Analysis (Ngs), Single-Gene Analysis (PCR Microarrays)

3) By Biomarker: Cell-Free Deoxyribonucleic Acid, Circulating Tumor Deoxyribonucleic Acid, Extracellular Vesicles, Circulating Tumor Cells, Other Biomarkers

4) By Clinical Application: Therapy Selection, Treatment Monitoring, Early Cancer Screening, Recurrence Monitoring, Other Applications

5) By End User: Diagnostics And Imaging Centres, Hospitals, Academics And Research Centers, Other End Users

Subsegments:

1) By Instruments: PCR Instruments, Microarray Instruments, Next-Generation Sequencing (NGS) Instruments

2) By Consumables Kits And Reagents: Sample Collection Kits, Amplification Reagents, Sequencing Reagents

3) By Software And Services: Data Analysis Software, Cloud-Based Services, Bioinformatics Tools

What Trends Are Shaping The Lung Cancer Liquid Biopsy Market Structure?

Major companies in the lung cancer liquid biopsy market are concentrating on advancing technologies, such as blood-based lung cancer screening tests, to improve early detection capabilities, enhance diagnostic precision, and allow for non-invasive, continuous monitoring of tumor progression and treatment outcomes. A blood-based lung cancer screening test represents a non-invasive method that examines biomarkers in the bloodstream to identify lung cancer at an early stage. For instance, in October 2023, DELFI Diagnostics Inc., a US-based biotechnology firm, introduced FirstLook Lung, a blood-based liquid biopsy test specifically developed to assist in the early detection of lung cancer. This test utilizes fragmentomics to pinpoint early lung cancer with high sensitivity and a 99.8% negative predictive value, providing an accessible and convenient initial step for at-risk individuals. Its aim is to boost early detection, increase screening participation, and help channel additional imaging resources to those who would most likely benefit.

Who Are The Firms Contributing To The Lung Cancer Liquid Biopsy Market Ecosystem?

Major companies operating in the lung cancer liquid biopsy market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Biocept Inc., Agilent Technologies Inc., Eurofins Scientific, Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Natera Inc., Myriad Genetics Inc., NeoGenomics Laboratories Inc., Guardant Health Inc., Exosome Diagnostics Inc., Menarini Silicon Biosystems S.p.A., Inivata Ltd, Lucence Diagnostics Pte Ltd, LungLife AI Inc., Biodesix Inc., Oncocyte Corporation

Access The Complete Lung Cancer Liquid Biopsy Market Report:

https://www.thebusinessresearchcompany.com/report/lung-cancer-liquid-biopsy-global-market-report

Which Area Represents The Largest Portion Of The Lung Cancer Liquid Biopsy Market?

North America was the largest region in the lung cancer liquid biopsy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lung cancer liquid biopsy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Lung Cancer Liquid Biopsy Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=24593&type=smp

Browse Through More Reports Similar to the Global Lung Cancer Liquid Biopsy Market 2026, By The Business Research Company

Lung Cancer Diagnostic And Screening Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/lung-cancer-diagnostic-and-screening-global-market-report

Liquid Biopsy Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/liquid-biopsy-global-market-report

Lung Cancer Drugs Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/lung-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Changes In Market Value Are Expected For The Lung Cancer Liquid Biopsy Market Over The 2026–2030 Period?

The lung cancer liquid biopsy market size has experienced swift growth in recent years. It is predicted to increase from $1.12 billion in 2025 to $1.31 billion by 2026, exhibiting a compound annual growth rate (CAGR) of 17.0%. The past growth in this market can be ascribed to a number of elements, including escalating lung cancer incidence rates, the limitations of tissue biopsy procedures, developments in molecular diagnostics, the availability of circulating biomarker technologies, and the expansion of oncology research endeavors.

The lung cancer liquid biopsy market size is projected to experience rapid growth in the upcoming years, with estimations indicating it will expand to $2.42 billion by 2030, achieving a compound annual growth rate (CAGR) of 16.7%. This expansion during the forecast period is primarily driven by the escalating demand for precision oncology solutions, the broadening of liquid biopsy clinical applications, the increasing adoption of companion diagnostics, the expanding integration of AI-driven data analysis, and a heightened focus on early cancer screening programs. Additionally, significant trends expected in the forecast period include a rising adoption of non-invasive diagnostic techniques, an increased utilization of NGS-based liquid biopsy tests, a growing demand for early cancer detection, the widening scope of personalized oncology diagnostics, and enhanced integration of bioinformatics platforms.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24593&type=smp

Which Key Drivers Are Affecting The Lung Cancer Liquid Biopsy Market Development?

The rising occurrence of lung cancer is anticipated to fuel the expansion of the lung cancer liquid biopsy market in the foreseeable future. Lung cancer defines a condition marked by the unchecked proliferation of atypical cells within the lungs, frequently stemming from smoking and environmental factors. Its prevalence is growing primarily because of persistent tobacco consumption, where smoking introduces carcinogens to the lungs, stimulating irregular cellular development. Lung cancer liquid biopsy offers assistance through the identification of cancer-associated genetic mutations and tumor DNA from blood specimens, facilitating prompt diagnosis, appropriate treatment selection, and continuous observation of disease advancement or therapeutic response. For example, in January 2023, data from a report issued by the American Cancer Society (ACS), a U.S.-based nonprofit organization, projected that in 2023, an estimated 238,340 individuals, comprising 117,550 men and 120,790 women, would receive a lung cancer diagnosis, with 127,070 people anticipated to succumb to the illness. Consequently, the rising incidence of lung cancer is a key factor propelling the expansion of the lung cancer liquid biopsy market.

What Are The Main Segments Within The Lung Cancer Liquid Biopsy Market Segment Structure?

The lung cancer liquid biopsy market covered in this report is segmented –

1) By Product: Instruments, Consumables, Kits And Reagents, Software And Services

2) By Technology: Multi-Gene-Parallel Analysis (Ngs), Single-Gene Analysis (PCR Microarrays)

3) By Biomarker: Cell-Free Deoxyribonucleic Acid, Circulating Tumor Deoxyribonucleic Acid, Extracellular Vesicles, Circulating Tumor Cells, Other Biomarkers

4) By Clinical Application: Therapy Selection, Treatment Monitoring, Early Cancer Screening, Recurrence Monitoring, Other Applications

5) By End User: Diagnostics And Imaging Centres, Hospitals, Academics And Research Centers, Other End Users

Subsegments:

1) By Instruments: PCR Instruments, Microarray Instruments, Next-Generation Sequencing (NGS) Instruments

2) By Consumables Kits And Reagents: Sample Collection Kits, Amplification Reagents, Sequencing Reagents

3) By Software And Services: Data Analysis Software, Cloud-Based Services, Bioinformatics Tools

What Trends Are Transforming The Lung Cancer Liquid Biopsy Market?

Major companies operating in the lung cancer liquid biopsy market are emphasizing the development of technological advancements, such as blood-based lung cancer screening tests, to boost early detection capabilities, refine diagnostic accuracy, and enable non-invasive, real-time monitoring of tumor progression and treatment response. A blood-based lung cancer screening test employs a non-invasive method to analyze biomarkers in the bloodstream, identifying lung cancer at an early stage. For instance, in October 2023, DELFI Diagnostics Inc., a US-based biotechnology company, launched FirstLook Lung, a blood-based liquid biopsy test designed to assist in early lung cancer detection. This test utilizes fragmentomics to detect early lung cancer with high sensitivity and a 99.8% negative predictive value, making it an accessible and convenient initial step for at-risk individuals. Its purpose is to enhance early detection, increase screening rates, and help direct further imaging resources to those most likely to benefit.

Who Are The Companies Participating In The Lung Cancer Liquid Biopsy Market?

Major companies operating in the lung cancer liquid biopsy market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Biocept Inc., Agilent Technologies Inc., Eurofins Scientific, Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Natera Inc., Myriad Genetics Inc., NeoGenomics Laboratories Inc., Guardant Health Inc., Exosome Diagnostics Inc., Menarini Silicon Biosystems S.p.A., Inivata Ltd, Lucence Diagnostics Pte Ltd, LungLife AI Inc., Biodesix Inc., Oncocyte Corporation

Get The Full Lung Cancer Liquid Biopsy Market Report:

https://www.thebusinessresearchcompany.com/report/lung-cancer-liquid-biopsy-global-market-report

Which Region Accounts For The Largest Portion Of The Lung Cancer Liquid Biopsy Market?

North America was the largest region in the lung cancer liquid biopsy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lung cancer liquid biopsy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Lung Cancer Liquid Biopsy Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/lung-cancer-liquid-biopsy-global-market-report

Browse Through More Reports Similar to the Global Lung Cancer Liquid Biopsy Market 2026, By The Business Research Company

Lung Cancer Diagnostic And Screening Market Report 2026

https://www.thebusinessresearchcompany.com/report/lung-cancer-diagnostic-and-screening-global-market-report

Liquid Biopsy Market Report

https://www.thebusinessresearchcompany.com/report/liquid-biopsy-global-market-report

Lung Cancer Drugs Market Report

https://www.thebusinessresearchcompany.com/report/lung-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Market Size Of The Lung Cancer Liquid Biopsy Market In 2026 And What Value Is Projected For 2030?

The lung cancer liquid biopsy market size has experienced rapid growth in recent years. This market is expected to expand from $1.12 billion in 2025 to $1.31 billion in 2026, achieving a compound annual growth rate (CAGR) of 17.0%. The expansion observed in the past can be linked to factors such as rising lung cancer incidence rates, the limitations inherent in tissue biopsy procedures, breakthroughs in molecular diagnostics, the widespread availability of circulating biomarker technologies, and an increase in oncology research endeavors.

The lung cancer liquid biopsy market is anticipated to experience substantial growth in the upcoming years. It is projected to expand to $2.42 billion by 2030, driven by a compound annual growth rate (CAGR) of 16.7%. This expansion during the forecast period is attributable to the increasing demand for precision oncology solutions, the broadening of liquid biopsy clinical applications, a rise in the adoption of companion diagnostics, the growing integration of AI-driven data analysis, and an increased focus on early cancer screening programs. Significant trends expected during this period include the rising adoption of non-invasive diagnostic techniques, increased utilization of NGS-based liquid biopsy tests, a growing demand for early cancer detection, the expansion of personalized oncology diagnostics, and enhanced integration of bioinformatics platforms.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24593&type=smp

What Drivers Are Influencing The Lung Cancer Liquid Biopsy Market?

The rising occurrence of lung cancer is projected to drive expansion within the lung cancer liquid biopsy market in the coming period. This condition involves the unchecked proliferation of atypical cells in the lungs, frequently stemming from tobacco use and exposure to environmental factors. The primary reason for the rise in lung cancer cases is ongoing tobacco consumption, as smoking introduces carcinogens to the lungs, stimulating irregular cell development. A lung cancer liquid biopsy aids in identifying genetic mutations linked to cancer and tumor DNA through a blood specimen, facilitating prompt diagnosis, choice of treatment, and tracking of disease advancement or therapeutic effectiveness. For example, a report from the American Cancer Society (ACS), a U.S.-based nonprofit organization, indicated in January 2023 that approximately 238,340 individuals, comprising 117,550 men and 120,790 women, are projected to receive a lung cancer diagnosis in 2023, with an anticipated 127,070 people succumbing to the illness. Consequently, the growing prevalence of lung cancer is fueling the expansion of the lung cancer liquid biopsy market.

What Are The Key Segments Of The Lung Cancer Liquid Biopsy Market?

The lung cancer liquid biopsy market covered in this report is segmented –

1) By Product: Instruments, Consumables, Kits And Reagents, Software And Services

2) By Technology: Multi-Gene-Parallel Analysis (Ngs), Single-Gene Analysis (PCR Microarrays)

3) By Biomarker: Cell-Free Deoxyribonucleic Acid, Circulating Tumor Deoxyribonucleic Acid, Extracellular Vesicles, Circulating Tumor Cells, Other Biomarkers

4) By Clinical Application: Therapy Selection, Treatment Monitoring, Early Cancer Screening, Recurrence Monitoring, Other Applications

5) By End User: Diagnostics And Imaging Centres, Hospitals, Academics And Research Centers, Other End Users

Subsegments:

1) By Instruments: PCR Instruments, Microarray Instruments, Next-Generation Sequencing (NGS) Instruments

2) By Consumables Kits And Reagents: Sample Collection Kits, Amplification Reagents, Sequencing Reagents

3) By Software And Services: Data Analysis Software, Cloud-Based Services, Bioinformatics Tools

Which Trends Are Shaping The Future Of The Lung Cancer Liquid Biopsy Market?

Major companies operating in the lung cancer liquid biopsy market are prioritizing the development of technological advancements, including blood-based lung cancer screening tests, to enhance early detection capabilities, improve diagnostic accuracy, and enable non-invasive, real-time monitoring of tumor progression and treatment response. A blood-based lung cancer screening test represents a non-invasive method that analyzes specific biomarkers in the bloodstream to identify the presence of lung cancer at an early stage. For instance, in October 2023, DELFI Diagnostics Inc., a US-based biotechnology company, launched FirstLook Lung, a blood-based liquid biopsy test specifically designed to aid in early lung cancer detection. This test leverages fragmentomics to detect early lung cancer with high sensitivity and features a 99.8% negative predictive value, making it a convenient and accessible initial step for at-risk individuals. Its purpose is to improve early detection, increase screening rates, and help direct further imaging resources to those most likely to benefit.

Who Are The Leading Companies Operating In The Lung Cancer Liquid Biopsy Market?

Major companies operating in the lung cancer liquid biopsy market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Biocept Inc., Agilent Technologies Inc., Eurofins Scientific, Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Natera Inc., Myriad Genetics Inc., NeoGenomics Laboratories Inc., Guardant Health Inc., Exosome Diagnostics Inc., Menarini Silicon Biosystems S.p.A., Inivata Ltd, Lucence Diagnostics Pte Ltd, LungLife AI Inc., Biodesix Inc., Oncocyte Corporation

Read the full lung cancer liquid biopsy market report here:

https://www.thebusinessresearchcompany.com/report/lung-cancer-liquid-biopsy-global-market-report

Which Regions Are Expected To Experience Rapid Expansion In The Lung Cancer Liquid Biopsy Market?

North America was the largest region in the lung cancer liquid biopsy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lung cancer liquid biopsy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Lung Cancer Liquid Biopsy Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24593&type=smp

Browse Through More Reports Similar to the Global Lung Cancer Liquid Biopsy Market 2026, By The Business Research Company

Lung Cancer Diagnostic And Screening Global Market Report

https://www.thebusinessresearchcompany.com/report/lung-cancer-diagnostic-and-screening-global-market-report

Liquid Biopsy Global Market Report

https://www.thebusinessresearchcompany.com/report/liquid-biopsy-global-market-report

Lung Cancer Drugs Global Market Report

https://www.thebusinessresearchcompany.com/report/lung-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model